Immunosuppression in Renal Transplantation

Andrew Bland, MD, MBA, MS

Overview

Post-transplant immunosuppression represents a delicate balance between preventing allograft rejection and minimizing drug toxicity and infection risk. Modern immunosuppressive regimens achieve excellent short-term outcomes (>95% one-year graft survival in living-donor kidneys) but long-term challenges—chronic kidney disease in the graft, late acute rejection, CNI toxicity, and malignancy—persist. Understanding the mechanism of action, drug interactions, therapeutic drug monitoring (TDM), and non-adherence as the #1 cause of late graft loss is essential for nephrologists managing transplant patients.

High-Yield Board Point

Induction therapy: Basiliximab (IL-2 antagonist) or ATG (antithymocyte globulin) ± alemtuzumab. Maintenance triple therapy (standard): Calcineurin inhibitor (tacrolimus preferred over cyclosporine; target trough 8–12 ng/mL year 1, 6–10 ng/mL year 2+) + mycophenolate mofetil (1–3 g/day) + prednisone (taper to 5–10 mg/day). Key challenges: CNI nephrotoxicity (dose-dependent), non-adherence (leading cause of late graft loss), BK virus (polyomavirus), PTLD (post-transplant lymphoproliferative disorder), malignancy. TDM critical: Tacrolimus has narrow therapeutic window; target levels individualized.

Historical Evolution

Era	Regimen	1-Year Graft Survival	5-Year Graft Survival
Pre-1980s	Azathioprine + prednisone	~70%	~40%
Cyclosporine Era (1980s–2000s)	Cyclosporine + azathioprine + prednisone	~85%	~65%
Modern Era (2000s–present)	Tacrolimus + MMF + prednisone + induction	~96% (living-donor)	~70–75%

Immunologic Principles

Allograft Rejection Mechanisms

Acute Cellular Rejection (ACR)

T-cell mediated; CD8+ cytotoxic T cells and CD4+ helper T cells infiltrate graft
Results from insufficient CNI/antimetabolite therapy
Incidence: 10–20% in modern series (down from 40–60% in 1990s)
Often reversible with pulse steroids or antibody therapy

Acute Antibody-Mediated Rejection (AMR)

Humoral immune response; donor-specific antibodies (DSA) bind HLA/non-HLA antigens
Complement activation (C4d deposition in peritubular capillaries); endothelial injury
More refractory to treatment than ACR
De novo DSA formation: 5–10% per year post-transplant

Chronic Rejection

Combination of cellular and humoral alloimmunity
Pathology: Chronic allograft nephropathy (CAN) — intimal fibrosis, glomerular sclerosis
Progressive graft dysfunction (proteinuria, GFR decline)
Often irreversible; leads to late graft loss

Mechanisms of Key Agents

Calcineurin Inhibitors (CNI)

Tacrolimus and cyclosporine inhibit calcineurin phosphatase
Calcineurin normally dephosphorylates NFAT (nuclear factor of activated T cells)
CNI blockade → NFAT remains phosphorylated → stays in cytoplasm → cannot enter nucleus
Result: Reduced IL-2 transcription → T cell proliferation inhibited

Mycophenolate Mofetil (MMF)

Prodrug of mycophenolic acid (MPA)
Selectively inhibits inosine monophosphate dehydrogenase (IMPDH) type II
IMPDH type II preferentially expressed in lymphocytes
Inhibition → reduced guanosine synthesis → reduced lymphocyte proliferation
Selective for T and B cells (other cell types use salvage pathway)

Induction Therapy

IL-2 Receptor Antagonists

Agent	Mechanism	Dosing	Advantages	Disadvantages
Basiliximab	Chimeric monoclonal Ab to IL-2R alpha chain	20 mg day 0, day 4	Well-tolerated; minimal systemic effects	Less effective in high-risk; fewer infections

T-Cell Depleting Agents

Antithymocyte Globulin (ATG, rabbit)

Polyclonal antibody; depletes T cells
Dosing: 1.5 mg/kg/day × 3–5 days
More potent than basiliximab; greater T-cell depletion
Side effects: Cytokine release syndrome (fever, chills, myalgia; mitigated by slow infusion)
Risk: Increased infection (CMV), PTLD from over-immunosuppression

Alemtuzumab

Anti-CD52 monoclonal antibody; profound T and B cell depletion
Dosing: 30 mg on day 0 and day 1 (typical)
Most potent depletion; excellent for high-risk patients
Risk: Very high infection/PTLD risk (requires close monitoring, CMV prophylaxis)
Reduced maintenance immunosuppression often possible

Clinical Pearl

Induction agent selection depends on immunologic risk: High-risk (retransplant, prior sensitization, PRA >50%) → T-cell depleting agent (ATG or alemtuzumab). Low-risk, older age, CMV+ → basiliximab. Standard induction: basiliximab (low-risk) vs. ATG (high-risk).

Maintenance Immunosuppression: Triple Therapy

Component 1: Calcineurin Inhibitor

Tacrolimus (Preferred)

Mechanism: CNI; more selective for T cells than cyclosporine
Dosing: Initial 0.1–0.3 mg/kg/day divided BID; titrate to trough levels
Target trough levels:
- Year 1 post-transplant: 8–12 ng/mL (peak efficacy window)
- Year 2+: 6–10 ng/mL (reduce toxicity while maintaining efficacy)
- Some centers use lower targets (5–7 ng/mL) in stable patients
Monitoring: Trough levels twice weekly initially, then weekly × 1 month, then every 1–3 months
Metabolism: Hepatic (CYP3A4); highly protein-bound
Nephrotoxicity: Dose-dependent; afferent arteriolar vasoconstriction and CAN
Advantages over cyclosporine: Better graft survival (SYMPHONY trial), less HTN, easier TDM

Cyclosporine (Less Common)

Older CNI; more nephrotoxic, more HTN induction, less T-cell selective
Target trough 100–200 ng/mL (or C2 600–800 ng/mL)

Component 2: Antimetabolite

Mycophenolate Mofetil (MMF)

Mechanism: Selective IMPDH type II inhibitor; reduces lymphocyte proliferation
Dosing: 1–3 g/day (divided BID or TID)
Efficacy: Reduces acute rejection rate by ~50% compared to azathioprine
GI side effects: Diarrhea (30–40%), nausea; manage with enteric-coated form
No TDM needed (variable absorption); some use MPA AUC if severe GI issues

Warning

MMF is teratogenic (category D). Avoid in women of childbearing age or ensure reliable contraception. Switch to azathioprine prior to planned pregnancy.

Component 3: Corticosteroids

Mechanism: Nuclear transcription factor; suppresses IL-2, TNF-alpha, other cytokines
Initial dose: 20–30 mg/day (day 0, post-transplant)
Taper schedule:
- Week 1: 20–30 mg/day
- Month 1: 15 mg/day
- Month 3: 10 mg/day
- Month 6–12: 5 mg/day (maintenance)
Complications: HTN, hyperglycemia, weight gain, osteoporosis, infection susceptibility

Clinical Pearl

Steroid minimization/withdrawal: Modern regimens attempt to taper prednisone to the lowest possible dose (5–10 mg/day) due to long-term toxicity, but complete withdrawal increases rejection risk. Risk-benefit individualized based on rejection history, DSA status, and patient factors.

Newer/Alternative Immunosuppressive Agents

mTOR Pathway Inhibitors

Agent	Target Trough	Advantages	Disadvantages
Sirolimus	5–10 ng/mL	No CNI nephrotoxicity; less HTN; anti-angiogenic (may reduce malignancy risk)	GI side effects, hyperlipidemia, interstitial pneumonitis (rare), impaired wound healing
Everolimus	3–8 ng/mL	Better GI tolerability than sirolimus	Similar profile to sirolimus

Belatacept (Costimulation Blockade)

Mechanism: CTLA-4-Ig fusion protein; blocks CD80/CD86 costimulatory molecules (prevents T-cell second signal)
Dosing: IV 5 mg/kg on days 0, 4, 14, 28, 56, 84 (loading), then every 4 weeks maintenance
Advantages: No CNI nephrotoxicity; potential reduced malignancy; good long-term graft survival
Disadvantages: IV only (requires infusion center); PTLD risk if EBV-seronegative; higher early cellular rejection

Therapeutic Drug Monitoring & Drug Interactions

TDM Targets

Drug	Target Level	Timing	Method	Year 1 Frequency
Tacrolimus	8–12 ng/mL (Y1); 6–10 ng/mL (Y2+)	Pre-dose (trough)	LC-MS/MS (gold standard)	2×/wk → weekly → biweekly → monthly
Cyclosporine	100–200 ng/mL	Pre-dose	HPLC or LC-MS/MS	Similar
Sirolimus	5–10 ng/mL	Pre-dose	LC-MS/MS	Similar to tacrolimus
Everolimus	3–8 ng/mL	Pre-dose	LC-MS/MS	Similar to tacrolimus

Major CYP3A4 Interactions (Tacrolimus)

Inhibitors (Increase Tacrolimus Levels — Toxicity Risk)

Antibiotics: Macrolides (erythromycin, azithromycin); fluoroquinolones
Antifungals: Fluconazole, itraconazole, voriconazole (avoid if possible; reduce tacrolimus dose)
Antiretrovirals: Ritonavir (boosting agent)
Other: Cimetidine, diltiazem, verapamil, grapefruit juice

Inducers (Decrease Tacrolimus Levels — Subtherapeutic Risk)

Anticonvulsants: Phenytoin, phenobarbital, carbamazepine
Antibiotics: Rifampicin/rifampin (potent inducer; avoid)
Other: St. John’s wort (herbal; avoid)

Warning: Generic Tacrolimus Formulations

Different generic formulations have different bioavailability. Switching brands can cause subtherapeutic or toxic levels. Maintain consistent formulation if possible. If switch unavoidable: close TDM (check trough 5–7 days post-switch); adjust dose as needed.

Non-Adherence: The #1 Cause of Late Graft Loss

Epidemiology

~20–25% of renal transplant patients are non-adherent to immunosuppression
Adherence worsens over time (years 3–5: 30–40% non-adherent)
Non-adherence associated with 2–3× higher risk of graft loss

Causes of Non-Adherence

Category	Examples
Intentional	Belief that reduced dose is safe; desire to “test” kidney; intentional missed doses
Unintentional	Forgetfulness; complex regimen; cost/insurance barriers; side effects
Psychosocial	Depression, anxiety, substance abuse, denial of transplant
Side effects	GI issues (MMF), HTN (CNI), tremor (CNI), acne (steroids)
Access/cost	Pharmacy access, medication cost, out-of-pocket expenses

Interventions to Improve Adherence

Education: Emphasize graft dependence on immunosuppression; explain consequences
Simplification: Once-daily formulations if possible; reduce number of agents
Reminder systems: Phone alerts, pill organizers, pharmacy calls
Psychosocial support: Mental health screening; intervention if depression/substance abuse
Cost assistance: Pharmaceutical patient assistance programs; navigate insurance barriers
Frequent monitoring: Close contact with transplant team; early identification

Clinical Pearl

Late acute rejection (years 1–5) is increasingly recognized as primarily due to non-adherence rather than immunologic failure. Always suspect non-adherence (check tacrolimus level) when acute rejection develops in a stable transplant patient. Non-adherence is preventable; intervention is critical.

CNI Nephrotoxicity, Viral Complications, and Malignancy

CNI Nephrotoxicity

Acute CNI Nephrotoxicity

Dose-dependent; reversible
Mechanism: Afferent arteriolar vasoconstriction; reduced GFR
Manifests as rising creatinine with elevated trough levels
May mimic acute rejection (distinguished by biopsy or CNI level reduction + Cr improvement)

Chronic CNI Nephrotoxicity (CAN)

Cumulative, irreversible arteriolopathy/tubulointerstitial fibrosis
Pathology: Tubular atrophy, interstitial fibrosis, arteriolar hyalinosis
Develops despite “normal” trough levels (time-dependent)
Contributes to long-term graft dysfunction

Management

Reduce CNI dose: Decrease tacrolimus; check trough in 3–5 days; reassess Cr after 1–2 weeks
Switch CNI: Cyclosporine to tacrolimus (or vice versa)
CNI-sparing regimen: Add sirolimus or everolimus; reduce CNI dose while maintaining IS

Clinical Pearl

ACE-I/ARB are generally protective and should be used in renal transplant patients for HTN management and graft protection (reduce proteinuria, slow graft decline). Do NOT avoid ACE-I/ARB in transplant; monitor Cr/K+ but they are beneficial.

BK Polyomavirus Nephropathy (BKVN)

Mechanism: BK virus reactivation in immunocompromised patients; direct viral cytolysis of tubular epithelium
Incidence: 1–5% of renal transplants (higher with tacrolimus than cyclosporine)
Presentation: Asymptomatic rise in creatinine (months 3–12 post-transplant typical)
Diagnosis:
- Plasma BK viral load: >100 copies/mL suggests viremia; >1000 copies/mL concerning
- Urine BK viral load: >10⁷ copies/mL suggests active replication
- Kidney biopsy: Nuclear inclusions, inflammation, fibrosis (confirms diagnosis)
Management: Reduce immunosuppression (decrease CNI and/or antimetabolite); quarterly monitoring
Prognosis: If caught early (low viral load), ~70% respond to reduced IS; if delayed, progressive graft loss likely

Cytomegalovirus (CMV)

Risk: ~20% of CMV-seronegative recipients of seropositive donor (D+/R-) without prophylaxis
Prophylaxis: Valganciclovir 900 mg PO daily × 3–6 months (for D+/R- or high-risk)
Clinical disease: Fever, leukopenia, viral syndrome, colitis, esophagitis (rare now with prophylaxis)

Malignancy and PTLD Risk

Post-Transplant Lymphoproliferative Disorder (PTLD)

Spectrum from benign lymphoid hyperplasia to frank lymphoma
EBV-associated (90% of cases): Risk highest in EBV-seronegative recipients
Risk increased with T-cell depleting induction (ATG, alemtuzumab >> basiliximab)
Incidence: 1–2% in modern series; higher (5–10%) with alemtuzumab

Solid Malignancy

Skin cancer: 20–40× higher (monitor skin regularly)
Cervical cancer: HPV screening/vaccination recommended
Lymphomas: EBV-related and non-EBV
Lung, kidney, liver, colon cancers: 2–3× general population

Cancer Prevention in Transplant

Minimize immunosuppression over time (reasonable goal). Screen for cancer (skin exams, cervical cytology, colonoscopy per guidelines). Vaccinate pre-transplant (HPV vaccine) when possible. If EBV-seronegative, use less aggressive induction (basiliximab > ATG); monitor EBV viral load in year 1.

References

Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9 Suppl 3:S1-S155. PubMed
Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation (SYMPHONY trial). N Engl J Med. 2007;357(25):2562-2575. PubMed